Vet Med - Czech, 2023, 68(4):135-144 | DOI: 10.17221/65/2022-VETMED
Citalopram in vitro metabolism in a beagle dog: A role for CYP2D15 in the production of toxic didesmethylcitalopram?Original Paper
- 1 Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 2 Department of Education and Research, University of Lausanne, Lausanne, Switzerland
- 3 School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland, and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
- 4 PharmaciePlus Franches-Montagnes, Saignelégier, Switzerland
After administration of the serotonergic antidepressant citalopram (CIT) to beagle dogs, they may experience severe convulsive attacks in relation with considerably higher plasma concentrations of the metabolite didesmethyl-CIT (DDCIT), when compared to those in humans medicated with CIT. This pilot study aimed at determining the role of cytochrome P-450 (CYP450) isozymes in the in vitro metabolism of CIT to desmethyl-CIT (DCIT), and of DCIT to DDCIT in the liver microsomes of a single beagle dog. The incubations with racemic CIT or DCIT reveal a high affinity enzyme with Km between 0.3 µM and 1.4 µM for S- and R-DCIT and S- and R-DDCIT productions, respectively. In comparison to human enzymes, the intrinsic clearance values of this high affinity enzyme are between 15 µL/(min x mg of protein) and 52 µL/(min x mg of protein), i.e. very high. In vitro experiments with inhibitors suggest that CYP2D15, which shows analogy with human CYP2D6, is by far the main CYP450 isozyme involved in the production of DCIT and DDCIT whereas CYP3A12 and CYP2C21/41 showed a weak implication. These observations partly explain why in humans, plasma concentrations of the toxic DDCIT are considerably lower than those observed in dogs, after administration of CIT.
Keywords: Cytochrome P-450; liver microsomes; stereoselectivity
Received: July 16, 2022; Accepted: March 13, 2023; Published: April 28, 2023 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Baumann P, Bertschy G, Ramseier F, Nil R. Plasma concentrations and cardiovascular effects of citalopram enantiomers after oral versus infusion citalopram therapy in dextromethorphan-mephenytoin-phenotyped patients with major depression. Ther Drug Monit. 2021 Jun 1;43(3):436-42.
Go to original source...
Go to PubMed...
- Boeck V, Overo KF, Svendsen O. Studies on acute toxicity and drug levels of citalopram in the dog. Acta Pharmacol Toxicol (Copenh). 1982 Mar;50(3):169-74.
Go to original source...
Go to PubMed...
- Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B. Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica. 2000 Dec;30(12):1131-52.
Go to original source...
Go to PubMed...
- Carlsson B, Norlander B. Optimization and characterization of the chiral separation of citalopram and its demethylated metabolites by response-surface methodology. Chromatographia. 2001;53(5-6):266-72.
Go to original source...
- Carlsson B, Olsson G, Reis M, Walinder J, Nordin C, Lundmark J, Scordo MG, Dahl ML, Bengtsson F, Ahlner J. Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monit. 2001 Dec;23(6):658-64.
Go to original source...
Go to PubMed...
- Chauret N, Gauthier A, Martin J, Nicoll-Griffith DA. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos. 1997 Oct;25(10):1130-6.
- Court MH. Canine cytochrome P-450 pharmacogenetics. Vet Clin North Am Small Anim Pract. 2013 Sep;43(5):1027-38.
Go to original source...
Go to PubMed...
- Dayer P, Kronbach T, Eichelbaum M, Meyer UA. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol. 1987 Dec 1;36(23):4145-52.
Go to original source...
Go to PubMed...
- Fanoe S, Kristensen D, Fink-Jensen A, Jensen HK, Toft E, Nielsen J, Videbech P, Pehrson S, Bundgaard H. Risk of arrhythmia induced by psychotropic medications: A proposal for clinical management. Eur Heart J. 2014 May 21;35(20):1306-15.
Go to original source...
Go to PubMed...
- FDA - The United States Food and Drug Administration. Celexa® (citalopram hydrobromide) [Internet]. 2017 [cited 2022 Jun 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf.
- Fredricson Overo K, Hojelse F. The unexpected preclinical finding - Elucidation of dog toxicity - Citalopram. In: Proceedings of the Association of the Swedish Pharmaceutical Industry on the Use of Pharmacology Studies in Drug Safety Assessment - Present Situation and Future Perspective; 1994. p. 113-5.
- Fredricson Overo K. Kinetics of citalopram in test animals; drug exposure in safety studies. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):297-309.
Go to original source...
Go to PubMed...
- Fredricson Overo K. The pharmacokinetic and safety evaluation of citalopram from preclinical and clinical data. In: Montgomery SA, editor. Citalopram. The new antidepressant from Lundbeck research. Amsterdam: Excerpta Medica; 1989. p. 22-30.
- Herrlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson LL, Bertilsson L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol. 2003 Oct;56(4):415-21.
Go to original source...
Go to PubMed...
- Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect. 1992;88(2):157-60.
Go to original source...
Go to PubMed...
- Hyttel J. Comparative pharmacology of selective serotonin re-uptake inhibitors (SSRIs). Nord J Psychiatry. 1993;47(Suppl_30):5-12.
Go to original source...
- Karakus E, Prinzinger C, Leiting S, Geyer J. Sequencing of the canine cytochrome P450 CYP2C41 gene and genotyping of its polymorphic occurrence in 36 dog breeds. Front Vet Sci. 2021 Apr 22;8:663175.
Go to original source...
Go to PubMed...
- Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther. 1997 Feb;280(2):927-33.
Go to original source...
- Kosel M, Eap CB, Amey M, Baumann P. Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998 Nov 20;719(1-2):234-8.
Go to original source...
Go to PubMed...
- Kuroha M, Azumano A, Kuze Y, Shimoda M, Kokue E. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450.3A substrate in Beagle dogs. Drug Metab Dispos. 2002 Jan;30(1):63-8.
Go to original source...
Go to PubMed...
- Le Bloc'h Y, Woggon B, Weissenrieder H, Brawand-Amey M, Spagnoli J, Eap CB, Baumann P. Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. Ther Drug Monit. 2003 Oct;25(5):600-8.
Go to original source...
Go to PubMed...
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265-75.
Go to original source...
- Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):875-94.
Go to original source...
Go to PubMed...
- Martinez MN, Antonovic L, Court M, Dacasto M, Fink-Gremmels J, Kukanich B, Locuson C, Mealey K, Myers MJ, Trepanier L. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metab Rev. 2013 May;45(2):218-30.
Go to original source...
Go to PubMed...
- Matsui E, Hoshino M, Matsui A, Okahira A. Simultaneous determination of citalopram and its metabolites by high-performance liquid chromatography with column switching and fluorescence detection by direct plasma injection. J Chromatogr B Biomed Appl. 1995 Jun 23;668(2):299-307.
Go to original source...
Go to PubMed...
- Olesen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology. 1999 Dec;59(6):298-309.
Go to original source...
Go to PubMed...
- Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: Prospective trials and retrospective analyses. J Clin Psychopharmacol. 1999 Oct;19(5):407-15.
Go to original source...
Go to PubMed...
- Rochat B, Amey M, Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit. 1995 Jun;17(3):273-9.
Go to original source...
Go to PubMed...
- Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics. 1997 Feb;7(1):1-10.
Go to original source...
Go to PubMed...
- Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol. 1998 Jul 1;56(1):15-23.
Go to original source...
Go to PubMed...
- Rudberg I, Reubsaet JL, Hermann M, Refsum H, Molden E. Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro. Drug Metab Dispos. 2009 Dec;37(12):2340-8.
Go to original source...
Go to PubMed...
- Sakai C, Iwano S, Yamazaki Y, Ando A, Nakane F, Kouno M, Yamazaki H, Myamoto Y. Species differences in the pharmacokinetic parameters of cytochrome P450 probe substrates between experimental animals, such as mice, rats, dogs, monkeys, and microminipigs, and humans. J Drug Metab Toxicol. 2014;5(6):1000173.
Go to original source...
- Shanks N, Greek R, Greek J. Are animal models predictive for humans? Philos Ethics Humanit Med. 2009 Jan 15;4:2.
Go to original source...
Go to PubMed...
- Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y, Mei Q, Rodrigues AD, Rushmore TH. Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. Drug Metab Dispos. 2003 Sep;31(9):1161-9.
Go to original source...
Go to PubMed...
- Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality. 1997;9(7):686-92.
Go to original source...
- Sindrup SH, Brosen K, Hansen MG, Aaes-Jorgensen T, Overo KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 1993 Feb;15(1):11-7.
Go to original source...
Go to PubMed...
- Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, Pasanen M. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: A comparative study in vitro. Xenobiotica. 2007 Dec;37(12):1367-77.
Go to original source...
Go to PubMed...
- van Hagen MAE, Schipper L, Oosterveer-van der Doelen MAM, Vos-Loohuis M, Gehring R, Leegwater PA. Analysis of polymorphisms of canine Cytochrome P 450-CYP2D15. J Vet Pharmacol Ther. 2020 Nov;43(6):602-7.
Go to original source...
Go to PubMed...
- von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS, Shader RI. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999 Sep 15;46(6):839-49.
Go to original source...
Go to PubMed...
- von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001 Aug;29(8):1102-9.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.